Niagen Bioscience shares fell 16.5% after earnings, with investors likely focused on continued competitive pressure in the ingredients business and pricing hurdles for a large customer. Management also framed 2026 as an investment year, with growth initiatives and expected commercialization of a lower-cost ingredient salt form largely aimed at 2027.
- The company reported approximately $2.6 million in positive operating cash flow and $455,000 in adjusted EBITDA for the quarter; it ended with $69.5 million in cash, no debt, and $83.3 million in working capital.
- Website revenue grew approximately 10% year over year, or 17% adjusted for the timing of Prime Day.
- Management said one large ingredients customer faces continued competition from NMN and other products, while pricing remains a hurdle for ingredient customers and end users.
- A new NR salt form is undergoing ingredient qualification, with commercialization expected in early 2027; the company said it could lower manufacturing costs and customer prices.
- Growth plans include expanded retail distribution, new Tru Niagen and skin-care products, and clinic partnerships. A topical product through a global skin-care partner is expected in early 2027, and a branded skin-care product is planned for the first half of 2027.
Community Discussion